Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models

Resistance to targeted EGFR inhibitors is likely to develop in EGFR mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detection of heterogeneous mechanisms of resistance within...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Cancer Res
المؤلفون الرئيسيون: Eberlein, Catherine A., Stetson, Daniel, Markovets, Aleksandra A., Al-Kadhimi, Katherine J., Lai, Zhongwu, Fisher, Paul R., Meador, Catherine B., Spitzler, Paula, Ichihara, Eiki, Ross, Sarah J., Ahdesmaki, Miika J., Ahmed, Ambar, Ratcliffe, Laura E., Christey O’Brien, Elizabeth L., Barnes, Claire H., Brown, Henry, Smith, Paul D., Dry, Jonathan R., Beran, Garry, Thress, Kenneth S., Dougherty, Brian, Pao, William, Cross, Darren A. E.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2015
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4605607/
https://ncbi.nlm.nih.gov/pubmed/25870145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-3167
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة